Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in a pre-planned transaction on September 5, 2025.
• He exercised employee stock options to acquire 73,176 shares of common stock at an exercise price of $25.30 per share.
• Concurrently, he sold 55,578 shares of common stock at a weighted average price of $46.01 per share, with individual sales ranging from $46.00 to $46.09.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 14, 2024.
• Following these transactions, Khattar directly beneficially owns 1,110,231 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust.
• He also holds 170,574 unexercised employee stock options.

Sentiment

Score: 6

Explanation: The CEO exercised options at a significantly lower price than the market sale price, indicating a profitable transaction. While a portion of shares were sold, the overall direct beneficial ownership increased slightly, and the transaction was pre-planned, suggesting routine equity management rather than a reaction to new information.

Positives

• CEO Jack Khattar exercised 73,176 employee stock options at $25.30, indicating a profitable transaction given the sale price of $46.01.
• The net effect of the direct transactions resulted in an increase of 17,598 shares in direct beneficial ownership for the CEO.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, suggesting a systematic approach to managing equity rather than a reaction to new, undisclosed information.

Negatives

• The sale of 55,578 shares, even under a 10b5-1 plan, reduces the CEO's direct exposure to the company's stock, which some investors might view as a slight reduction in conviction.

Future Outlook

This filing, a Form 4, reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to Supernus Pharmaceuticals and does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders may interpret the CEO's sale of shares, even under a 10b5-1 plan, with varying perspectives, potentially influencing short-term sentiment.
• The increase in direct beneficial ownership after the option exercise and partial sale could be viewed positively by investors as continued alignment of interests.

Key Dates

Recommendation

The filing reports a pre-planned insider transaction where the CEO exercised options and sold a portion of the acquired shares. While the sale reduces direct holdings, the overall beneficial ownership (direct + indirect) remains substantial, and the transaction was executed under a 10b5-1 plan, suggesting it is not a reaction to new, undisclosed information. This type of routine insider activity typically warrants a 'hold' as it does not fundamentally alter the investment thesis for the company.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Stock Options, Share Sale, Jack Khattar, 10b5-1 Plan, Biotechnology, Pharmaceuticals